Trastuzumab Rezetecan in ERBB2-Low Advanced Breast Cancer

Trastuzumab rezetecan provided significant progression-free survival benefit over physician’s choice of chemotherapy in patients with ERBB2-low advanced breast cancer, with benefit observed across all key subgroups. It exhibited the potential as a new treatment option with a distinct safety profile in this setting.

Corresponding Author: Binghe Xu, MD, PhD, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Innovative Drug Research and Translational Study for Breast Cancer and State Key Laboratory of Advanced Medical Materials and Devices, 17 Panjiayuan South Lane, Chaoyang District, Beijing, 100021, China (xubinghe@medmail.com.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.